Article Information
History
- November 21, 2022.
Article Versions
- Version 1 (November 10, 2022 - 14:01).
- You are currently viewing Version 2 of this article (November 21, 2022 - 14:24).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Hythem Sidky, PhD1,†,*,
- David K. Sahner, MD1,†,*,
- Andrew T. Girvin, PhD2,
- Nathan Hotaling, PhD1,
- Sam G. Michael,
- Michael G. Kurilla, MD, PhD1,
- Ken Gersing, MD1 and
- the N3C consortium
- 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD
- 2Palantir Technologies, Denver, CO
- ↵*Corresponding authors. hythem.sidky{at}nih.gov, david.sahner{at}nih.gov
↵† These authors contributed equally.
Posted November 21, 2022.
Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19
